Nukkleus [NUKKW] vs Salesforce [CRM] Detailed Stock Comparison
Nukkleus
NASDAQ
Loading...
Salesforce
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Nukkleus wins in 6 metrics, Salesforce wins in 7 metrics, with 0 ties. Salesforce appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Nukkleus | Salesforce | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 38.47 | N/A |
| Price-to-Book Ratio | N/A | 3.88 | N/A |
| Debt-to-Equity Ratio | -0.04 | 19.81 | Nukkleus |
| PEG Ratio | N/A | 20.26 | N/A |
| EV/EBITDA | -118.82 | 20.49 | Nukkleus |
| Profit Margin (TTM) | 16.89% | 16.08% | Nukkleus |
| Operating Margin (TTM) | -134.75% | 20.12% | Salesforce |
| EBITDA Margin (TTM) | N/A | 20.12% | N/A |
| Return on Equity | 120.02% | 10.31% | Nukkleus |
| Return on Assets (TTM) | -864.83% | 5.09% | Salesforce |
| Free Cash Flow (TTM) | $-3.82M | $12.43B | Salesforce |
| Dividend Yield | N/A | 0.62% | N/A |
| 1-Year Return | 166.67% | -5.95% | Nukkleus |
| Price-to-Sales Ratio (TTM) | 152.42 | 6.09 | Salesforce |
| Enterprise Value | $905.35M | $229.63B | Salesforce |
| EV/Revenue Ratio | 153.10 | 5.95 | Salesforce |
| Gross Profit Margin (TTM) | N/A | 76.96% | N/A |
| Revenue per Share (TTM) | N/A | $40 | N/A |
| Earnings per Share (Diluted) | $-0.02 | $6.39 | Salesforce |
| Beta (Stock Volatility) | -6.04 | 1.37 | Nukkleus |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Nukkleus vs Salesforce Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Nukkleus | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Salesforce | 1.00% | 2.41% | -5.80% | -12.40% | -19.47% | -24.91% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Nukkleus | 166.67% | -38.46% | -38.46% | -38.46% | -38.46% | -38.46% |
| Salesforce | -5.95% | 50.27% | -8.41% | 253.44% | 790.89% | 5,061.95% |
Performance & Financial Health Analysis: Nukkleus vs Salesforce
| Metric | NUKKW | CRM |
|---|---|---|
| Market Information | ||
| Market Cap | $901.35M | $235.01B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 62,610 | 9,471,510 |
| 90 Day Avg. Volume | 240,566 | 7,138,490 |
| Last Close | $0.03 | $248.29 |
| 52 Week Range | $0.03 - $0.03 | $226.48 - $369.00 |
| % from 52W High | 0.00% | -32.71% |
| All-Time High | $0.20 (Dec 25, 2023) | $369.00 (Dec 02, 2024) |
| % from All-Time High | -85.00% | -32.71% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.08% |
| Quarterly Earnings Growth | -1.00% | 0.01% |
| Financial Health | ||
| Profit Margin (TTM) | 0.17% | 0.16% |
| Operating Margin (TTM) | -1.35% | 0.20% |
| Return on Equity (TTM) | 1.20% | 0.10% |
| Debt to Equity (MRQ) | -0.04 | 19.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-9.94 | $63.33 |
| Cash per Share (MRQ) | $0.22 | $18.21 |
| Operating Cash Flow (TTM) | $-2,233,552 | $13.32B |
| Levered Free Cash Flow (TTM) | $-8,518,520 | $14.43B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.62% |
| Last 12-Month Dividend | N/A | $1.62 |
Valuation & Enterprise Metrics Analysis: Nukkleus vs Salesforce
| Metric | NUKKW | CRM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 38.47 |
| Forward P/E | N/A | 22.09 |
| PEG Ratio | N/A | 20.26 |
| Price to Sales (TTM) | 152.42 | 6.09 |
| Price to Book (MRQ) | N/A | 3.88 |
| Market Capitalization | ||
| Market Capitalization | $901.35M | $235.01B |
| Enterprise Value | $905.35M | $229.63B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 153.10 | 5.95 |
| Enterprise to EBITDA | -118.82 | 20.49 |
| Risk & Other Metrics | ||
| Beta | -6.04 | 1.37 |
| Book Value per Share (MRQ) | $-9.94 | $63.33 |
Financial Statements Comparison: Nukkleus vs Salesforce
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NUKKW | CRM |
|---|---|---|
| Revenue/Sales | $0 | $9.83B |
| Cost of Goods Sold | $0 | $4.53B |
| Gross Profit | $0 | $7.56B |
| Research & Development | N/A | $1.46B |
| Operating Income (EBIT) | $-1.51M | $1.98B |
| EBITDA | $-1.51M | $2.92B |
| Pre-Tax Income | $103.14M | $1.97B |
| Income Tax | $0 | $433.00M |
| Net Income (Profit) | $102.96M | $1.54B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NUKKW | CRM |
|---|---|---|
| Cash & Equivalents | $4.46M | $10.93B |
| Total Current Assets | $8.46M | $25.87B |
| Total Current Liabilities | $64.71M | $24.20B |
| Long-Term Debt | $1.01M | $10.78B |
| Total Shareholders Equity | $-57.22M | $60.67B |
| Retained Earnings | $-98.12M | $17.50B |
| Property, Plant & Equipment | $127,328 | $5.26B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NUKKW | CRM |
|---|---|---|
| Operating Cash Flow | $103.44M | $6.89B |
| Capital Expenditures | $-10,221 | N/A |
| Free Cash Flow | $-1.35M | $6.30B |
| Debt Repayment | N/A | $-179.00M |
| Common Stock Repurchase | N/A | $-2.63B |
Short Interest & Institutional Ownership Analysis
| Metric | NUKKW | CRM |
|---|---|---|
| Shares Short | 81,999 | 13.69M |
| Short Ratio | N/A | 2.29 |
| Short % of Float | N/A | 0.01% |
| Average Daily Volume (10 Day) | 62,610 | 9,471,510 |
| Average Daily Volume (90 Day) | 240,566 | 7,138,490 |
| Shares Outstanding | 2.10M | 962.00M |
| Float Shares | 3.46M | 930.65M |
| % Held by Insiders | N/A | 0.03% |
| % Held by Institutions | N/A | 0.83% |
Dividend Analysis & Yield Comparison: Nukkleus vs Salesforce
| Metric | NUKKW | CRM |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.62 |
| Last 12-Month Dividend Yield | N/A | 0.62% |
| 3-Year Avg Annual Dividend | N/A | $0.67 |
| 3-Year Avg Dividend Yield | N/A | 0.15% |
| 3-Year Total Dividends | N/A | $2.02 |
| Ex-Dividend Date | N/A | Apr 10, 2025 |